Bile duct cancer, also known as cholangiocarcinoma, is a rare disease wherein malignant cancer cells form from the bile duct. Bile duct forms off a network of different tubes that connects liver, small intestine, and the gall bladder. The smallest ducts combine to form hepatic duct, which eventually leads to liver. The bile passes from liver, then through the hepatic duct, and finally reaches the gall bladder. There are 2 types of bile duct cancer, intrahepatic bile duct cancer and extrahepatic bile duct cancer. Intrahepatic cancer, are also known as intrahepatic cholangiocarcinoma, are formed inside the liver, whereas it is vice versa in case of extrahepatic bile duct cancer. Furthermore, extrahepatic bile duct cancer is made up of hilum and distal regions. Few of the risk factors associated with bile duct cancer, which increase the chances of occurrence of cancer include primary sclerosing cholangitis, chronic ulcerative colitis, and bile duct cysts. Furthermore, few of the frequent symptoms and side effects associated with bile duct cancer include jaundice, hay fever, clay colored stool, and fever. Diagnosis is carried out through a slumber, including carcinogenic embryonic & CA 19-9 tumor marker test, magnetic resonance imaging (MRI), and ultrasound. Additionally, biopsy procedures such as laparoscopy and endoscopic retrograde cholangiopancreatography can be employed for obtaining a tissue sample to diagnose bile duct cancer in the patient.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the bile duct cancer drug market.
Top Impacting Factors
- Rising incidents of cases of bile duct cancer and liver cancer coupled with growing awareness on inception of advanced therapeutics for treatment of cancer and other chronic diseases is anticipated to drive market growth for bile duct cancer drugs market.
- Furthermore, advancements in endoscopic imaging techniques consisting of minimal invasive stone retrieval products are anticipated to drive market growth. The imaging is used to look and get insights into the interior of the body using high-tech CMOS imaging sensors.
- Further, rising in investments being influx into design and development of novel therapies for treatment of cancer coupled with growing awareness on the need on new age oncological medications is propelling further growth for bile duct cancer drug market.
- However, huge costs associated with bile duct cancer treatment and the inability of most pharmaceutical players to balance tradeoff between cost and response time/efficacy are likely to hinder bile duct cancer drug market. High fluctuations in prices is more evident in the U.S., Canada, and European countries.
Key Market Trends
- North America is expected to witness dominance in bile duct cancer treatment market, owing to rising cases of bile duct cancer in the regions coupled with more geriatric population under cover and increase in the need of advanced therapeutics for treatment of the disease.
- Asia-Pacific is expected to witness high gains, owing to a large population base and subsequent large pool of potential bile duct cancer patients coupled with growing awareness on inception of novel treatment therapeutics.
- Food and Drug administration (FDA) has recently granted permission for use of pemigatinib in the U.S. The medication is basically an oral kinase inhibitor and finds potential use in patients suffering from cholangiocarcinoma.
Key Benefits of the Report
- This study presents the analytical depiction of the bile duct cancer drug industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the bile duct cancer drug market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Bile Duct Cancer Drug Report
- Which are the leading players active in the bile duct cancer drug market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the bile duct cancer drug market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is bile duct cancer drug?
- What is the bile duct cancer drug market prediction in the future?
- What are the current trends and predicted trends?
Bile Duct Cancer Drug Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Distribution Channel |
|
 By Application |
|
 By Region |
|
 Key Market Players | Sanofi, Pfizer, Inc., Eli Lilly and Company, Fresenius Kabi AG, Accord Healthcare Inc., Kyowa Hakko Kirin Co Ltd., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, Delcath Systems Inc., Novartis AG, Celgene Corporation, Mylan N.V., Intercept Pharmaceuticals, Inc. |
Loading Table Of Content...
